Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population

. 2018 Nov;24(11):10.18553/jmcp.2018.17488. doi: 10.18553/jmcp.2018.17488

	Warfarin vs. Apixaban	P Value ^a	Dabigatran vs. Apixaban	P Value ^a	Rivaroxaban vs. Apixaban	P Value ^a
Stroke/SE, HR (95% CI)
Reduced dose^b	1.39 (0.72-2.67)	0.315	0.82 (0.29-2.28)	0.409	1.42 (0.83-2.42)	0.911
Standard dose^c	2.06 (1.37-3.10)	0.315	1.37 (0.71-2.65)	0.409	1.47 (1.01-2.13)	0.911
Major bleeding, HR (95% CI)
Reduced dose^b	1.52 (1.06-2.19)	0.803	1.89 (1.00-3.57)	0.763	1.23 (0.91-1.67)	0.039
Standard dose^c	1.61 (1.24-2.09)	0.803	1.69 (1.16-2.47)	0.763	1.81 (1.47-2.24)	0.039

^aP value is for interaction.

^bReduced dose: 2.5 mg apixaban, 75 mg dabigatran, 10 mg or 15 mg rivaroxaban.

^cStandard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban.

CI = confidence interval; HR = hazard ratio; SE = systemic embolism.